<div id="readability-page-1"><p>First Trust Advisors LP grew its position in  Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 39.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 251,817 shares of the biopharmaceutical company's stock after acquiring an additional 71,357 shares during the quarter. First Trust Advisors LP owned about 0.19% of Alnylam Pharmaceuticals worth $82,115,000 at the end of the most recent reporting period.</p><ul><li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li></ul><p>A number of other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in  Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock valued at $4,336,064,000 after purchasing an additional 240,534 shares during the last quarter.  T. Rowe Price Investment Management Inc. grew its stake in shares of  Alnylam Pharmaceuticals by 0.8% during the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after buying an additional 33,696 shares during the last quarter.  Price T Rowe Associates Inc. MD raised its holdings in shares of  Alnylam Pharmaceuticals by 5.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after buying an additional 185,783 shares during the period.  Geode Capital Management LLC lifted its stake in shares of  Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock worth $779,857,000 after acquiring an additional 75,936 shares during the last quarter.  Finally, Norges Bank purchased a new position in  Alnylam Pharmaceuticals during the 2nd quarter valued at $662,837,000. 92.97% of the stock is owned by hedge funds and other institutional investors. </p><h2>Alnylam Pharmaceuticals Trading Down 1.6%</h2><p>NASDAQ:ALNY opened at $458.12 on Friday. The firm has a 50-day simple moving average of $456.78 and a 200-day simple moving average of $403.01. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The firm has a market cap of $60.52 billion, a P/E ratio of 1,908.83 and a beta of 0.30. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>3 biotech powerhouses poised to thrive amid sector rebound</li></ul><p>A number of research firms have weighed in on ALNY. Bank of America increased their target price on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, September 17th. Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, October 6th. HC Wainwright  set a $570.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 4th. Oppenheimer  reissued an &#34;outperform&#34; rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, JPMorgan Chase &amp; Co. reduced their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an &#34;overweight&#34; rating on the stock in a research report on Monday, October 13th. Twenty-three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one  has given a Sell rating to the company's stock. According to data from MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and an average target price of $482.17.</p><p><b>View Our Latest Analysis on ALNY</b></p><h2>Insider Transactions at Alnylam Pharmaceuticals</h2><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>In other Alnylam Pharmaceuticals news, Director Colleen F. Reitan sold 18,000 shares of the business's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares in the company, valued at approximately $362,390. The trade was a 95.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 15,650 shares of the firm's stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the completion of the sale, the chief executive officer owned 65,409 shares in the company, valued at $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 78,328 shares of company stock worth $35,705,793. Company insiders own  1.50% of the company's stock. </p><h2>About Alnylam Pharmaceuticals</h2> (Free Report)<p>Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Alnylam Pharmaceuticals</li><li>What is Insider Trading? What You Can Learn from Insider Trading</li><li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li><li>Stock Market Upgrades: What Are They?</li><li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li><li>2 Fintech Stocks to Buy Now and 1 to Avoid</li><li>MarketBeat Week in Review – 12/1 - 12/5</li></ul><p><strong>Want to see what other hedge funds are holding ALNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALNY

<p>First Trust Advisors LP increased its stake in Alnylam Pharmaceuticals by 39.5% in Q2, owning 251,817 shares worth $82.1M. Alnylam's stock rose 65%, with analysts giving a "Moderate Buy" rating and an average target price of $482.17. Other investors like Vanguard and T. Rowe Price also increased their holdings. Alnylam's stock opened at $458.12, with a market cap of $60.52B.</p>

First Trust Advisors LP Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY